Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.24
PKI's Cash to Debt is ranked lower than
83% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.06 vs. PKI: 0.24 )
Ranked among companies with meaningful Cash to Debt only.
PKI' s Cash to Debt Range Over the Past 10 Years
Min: 0.09  Med: 0.33 Max: 2.06
Current: 0.24
0.09
2.06
Equity to Asset 0.51
PKI's Equity to Asset is ranked lower than
65% of the 183 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. PKI: 0.51 )
Ranked among companies with meaningful Equity to Asset only.
PKI' s Equity to Asset Range Over the Past 10 Years
Min: 0.24  Med: 0.50 Max: 0.63
Current: 0.51
0.24
0.63
Interest Coverage 7.53
PKI's Interest Coverage is ranked lower than
75% of the 93 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 166.12 vs. PKI: 7.53 )
Ranked among companies with meaningful Interest Coverage only.
PKI' s Interest Coverage Range Over the Past 10 Years
Min: 2.25  Med: 6.72 Max: 16.75
Current: 7.53
2.25
16.75
F-Score: 6
Z-Score: 3.07
M-Score: -2.63
WACC vs ROIC
6.07%
8.58%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 12.65
PKI's Operating margin (%) is ranked higher than
83% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.66 vs. PKI: 12.65 )
Ranked among companies with meaningful Operating margin (%) only.
PKI' s Operating margin (%) Range Over the Past 10 Years
Min: 4.75  Med: 9.42 Max: 10.56
Current: 12.65
4.75
10.56
Net-margin (%) 9.39
PKI's Net-margin (%) is ranked higher than
79% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.98 vs. PKI: 9.39 )
Ranked among companies with meaningful Net-margin (%) only.
PKI' s Net-margin (%) Range Over the Past 10 Years
Min: 0.4  Med: 7.21 Max: 22.94
Current: 9.39
0.4
22.94
ROE (%) 10.22
PKI's ROE (%) is ranked higher than
76% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.39 vs. PKI: 10.22 )
Ranked among companies with meaningful ROE (%) only.
PKI' s ROE (%) Range Over the Past 10 Years
Min: 0.41  Med: 7.93 Max: 22
Current: 10.22
0.41
22
ROA (%) 5.20
PKI's ROA (%) is ranked higher than
73% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.60 vs. PKI: 5.20 )
Ranked among companies with meaningful ROA (%) only.
PKI' s ROA (%) Range Over the Past 10 Years
Min: 0.22  Med: 4.28 Max: 12.48
Current: 5.2
0.22
12.48
ROC (Joel Greenblatt) (%) 61.04
PKI's ROC (Joel Greenblatt) (%) is ranked higher than
89% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.03 vs. PKI: 61.04 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
PKI' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 26.99  Med: 46.28 Max: 72.5
Current: 61.04
26.99
72.5
Revenue Growth (3Y)(%) 5.30
PKI's Revenue Growth (3Y)(%) is ranked lower than
51% of the 118 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.70 vs. PKI: 5.30 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
PKI' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -10.7  Med: 1.90 Max: 17.9
Current: 5.3
-10.7
17.9
EBITDA Growth (3Y)(%) 17.30
PKI's EBITDA Growth (3Y)(%) is ranked higher than
77% of the 99 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.90 vs. PKI: 17.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
PKI' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -20.9  Med: 6.05 Max: 35.2
Current: 17.3
-20.9
35.2
EPS Growth (3Y)(%) 421.70
PKI's EPS Growth (3Y)(%) is ranked higher than
99% of the 110 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.10 vs. PKI: 421.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
PKI' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -79  Med: 5.70 Max: 421.7
Current: 421.7
-79
421.7
» PKI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

PKI Guru Trades in Q1 2015

Steven Cohen 18,400 sh (New)
PRIMECAP Management 3,462,295 sh (+6.20%)
Ken Fisher 626,715 sh (+2.53%)
Vanguard Health Care Fund 1,441,400 sh (unchged)
Joel Greenblatt Sold Out
Chuck Royce 2,740,100 sh (-1.37%)
Jim Simons 138,500 sh (-44.15%)
» More
Q2 2015

PKI Guru Trades in Q2 2015

Ken Fisher 646,420 sh (+3.14%)
PRIMECAP Management 3,475,470 sh (+0.38%)
Vanguard Health Care Fund 1,441,400 sh (unchged)
Steven Cohen Sold Out
Chuck Royce 2,319,530 sh (-15.35%)
Jim Simons 68,600 sh (-50.47%)
» More
Q3 2015

PKI Guru Trades in Q3 2015

Ray Dalio 24,716 sh (New)
Joel Greenblatt 41,019 sh (New)
Louis Moore Bacon 126,581 sh (New)
Jim Simons 391,400 sh (+470.55%)
Ken Fisher 670,227 sh (+3.68%)
Vanguard Health Care Fund Sold Out
PRIMECAP Management 3,298,124 sh (-5.10%)
Chuck Royce 1,998,330 sh (-13.85%)
» More
Q4 2015

PKI Guru Trades in Q4 2015

Ken Fisher 661,620 sh (-1.28%)
Chuck Royce 706,430 sh (-64.65%)
» More
» Details

Insider Trades

Latest Guru Trades with PKI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 28.60
PKI's P/E(ttm) is ranked higher than
58% of the 149 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 31.20 vs. PKI: 28.60 )
Ranked among companies with meaningful P/E(ttm) only.
PKI' s P/E(ttm) Range Over the Past 10 Years
Min: 5.3  Med: 27.23 Max: 1582.5
Current: 28.6
5.3
1582.5
Forward P/E 14.51
PKI's Forward P/E is ranked higher than
75% of the 117 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 18.45 vs. PKI: 14.51 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 28.40
PKI's PE(NRI) is ranked higher than
57% of the 119 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 29.80 vs. PKI: 28.40 )
Ranked among companies with meaningful PE(NRI) only.
PKI' s PE(NRI) Range Over the Past 10 Years
Min: 11.52  Med: 27.90 Max: 1362
Current: 28.4
11.52
1362
P/B 2.36
PKI's P/B is ranked higher than
57% of the 242 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.58 vs. PKI: 2.36 )
Ranked among companies with meaningful P/B only.
PKI' s P/B Range Over the Past 10 Years
Min: 0.88  Med: 1.82 Max: 2.93
Current: 2.36
0.88
2.93
P/S 2.21
PKI's P/S is ranked higher than
55% of the 240 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.13 vs. PKI: 2.21 )
Ranked among companies with meaningful P/S only.
PKI' s P/S Range Over the Past 10 Years
Min: 0.72  Med: 1.79 Max: 2.76
Current: 2.21
0.72
2.76
PFCF 21.35
PKI's PFCF is ranked higher than
73% of the 131 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 24.30 vs. PKI: 21.35 )
Ranked among companies with meaningful PFCF only.
PKI' s PFCF Range Over the Past 10 Years
Min: 7.78  Med: 21.13 Max: 92.3
Current: 21.35
7.78
92.3
POCF 19.29
PKI's POCF is ranked higher than
55% of the 154 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.17 vs. PKI: 19.29 )
Ranked among companies with meaningful POCF only.
PKI' s POCF Range Over the Past 10 Years
Min: 6.33  Med: 17.22 Max: 42.44
Current: 19.29
6.33
42.44
EV-to-EBIT 25.31
PKI's EV-to-EBIT is ranked lower than
60% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.89 vs. PKI: 25.31 )
Ranked among companies with meaningful EV-to-EBIT only.
PKI' s EV-to-EBIT Range Over the Past 10 Years
Min: 10.6  Med: 23.30 Max: 59.2
Current: 25.31
10.6
59.2
EV-to-EBITDA 16.88
PKI's EV-to-EBITDA is ranked lower than
62% of the 177 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 13.88 vs. PKI: 16.88 )
Ranked among companies with meaningful EV-to-EBITDA only.
PKI' s EV-to-EBITDA Range Over the Past 10 Years
Min: 7  Med: 14.30 Max: 23.6
Current: 16.88
7
23.6
PEG 2.81
PKI's PEG is ranked lower than
55% of the 42 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.69 vs. PKI: 2.81 )
Ranked among companies with meaningful PEG only.
PKI' s PEG Range Over the Past 10 Years
Min: 0.58  Med: 2.62 Max: 230.82
Current: 2.81
0.58
230.82
Shiller P/E 29.80
PKI's Shiller P/E is ranked higher than
69% of the 49 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 37.56 vs. PKI: 29.80 )
Ranked among companies with meaningful Shiller P/E only.
PKI' s Shiller P/E Range Over the Past 10 Years
Min: 11.64  Med: 25.37 Max: 37.34
Current: 29.8
11.64
37.34
Current Ratio 1.94
PKI's Current Ratio is ranked lower than
61% of the 191 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.68 vs. PKI: 1.94 )
Ranked among companies with meaningful Current Ratio only.
PKI' s Current Ratio Range Over the Past 10 Years
Min: 0.74  Med: 1.66 Max: 2.13
Current: 1.94
0.74
2.13
Quick Ratio 1.37
PKI's Quick Ratio is ranked lower than
72% of the 191 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.41 vs. PKI: 1.37 )
Ranked among companies with meaningful Quick Ratio only.
PKI' s Quick Ratio Range Over the Past 10 Years
Min: 0.54  Med: 1.23 Max: 1.7
Current: 1.37
0.54
1.7
Days Inventory 87.42
PKI's Days Inventory is ranked higher than
52% of the 153 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 88.26 vs. PKI: 87.42 )
Ranked among companies with meaningful Days Inventory only.
PKI' s Days Inventory Range Over the Past 10 Years
Min: 65.31  Med: 75.45 Max: 81.17
Current: 87.42
65.31
81.17
Days Sales Outstanding 70.83
PKI's Days Sales Outstanding is ranked lower than
55% of the 155 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 65.71 vs. PKI: 70.83 )
Ranked among companies with meaningful Days Sales Outstanding only.
PKI' s Days Sales Outstanding Range Over the Past 10 Years
Min: 61.62  Med: 75.88 Max: 79.24
Current: 70.83
61.62
79.24
Days Payable 45.03
PKI's Days Payable is ranked lower than
59% of the 149 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 52.88 vs. PKI: 45.03 )
Ranked among companies with meaningful Days Payable only.
PKI' s Days Payable Range Over the Past 10 Years
Min: 51.51  Med: 58.18 Max: 64.02
Current: 45.03
51.51
64.02

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.64
PKI's Dividend Yield is ranked lower than
79% of the 82 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.42 vs. PKI: 0.64 )
Ranked among companies with meaningful Dividend Yield only.
PKI' s Dividend Yield Range Over the Past 10 Years
Min: 0.52  Med: 1.09 Max: 2.43
Current: 0.64
0.52
2.43
Dividend Payout 0.18
PKI's Dividend Payout is ranked higher than
90% of the 51 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.32 vs. PKI: 0.18 )
Ranked among companies with meaningful Dividend Payout only.
PKI' s Dividend Payout Range Over the Past 10 Years
Min: 0.03  Med: 0.29 Max: 3.5
Current: 0.18
0.03
3.5
Forward Dividend Yield 0.64
PKI's Forward Dividend Yield is ranked lower than
79% of the 71 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.49 vs. PKI: 0.64 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 0.62
PKI's Yield on cost (5-Year) is ranked lower than
78% of the 88 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.58 vs. PKI: 0.62 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
PKI' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0.52  Med: 1.09 Max: 2.43
Current: 0.62
0.52
2.43

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 1.50
PKI's Price/Projected FCF is ranked higher than
68% of the 114 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.06 vs. PKI: 1.50 )
Ranked among companies with meaningful Price/Projected FCF only.
PKI' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.52  Med: 1.35 Max: 131.1
Current: 1.5
0.52
131.1
Price/DCF (Earnings Based) 2.19
PKI's Price/DCF (Earnings Based) is ranked lower than
89% of the 28 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.76 vs. PKI: 2.19 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 1.23
PKI's Price/Median PS Value is ranked lower than
68% of the 238 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.96 vs. PKI: 1.23 )
Ranked among companies with meaningful Price/Median PS Value only.
PKI' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.29  Med: 0.90 Max: 1.87
Current: 1.23
0.29
1.87
Price/Peter Lynch Fair Value 1.67
PKI's Price/Peter Lynch Fair Value is ranked higher than
69% of the 42 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.31 vs. PKI: 1.67 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
PKI' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.74  Med: 3.02 Max: 166.76
Current: 1.67
0.74
166.76
Earnings Yield (Greenblatt) (%) 4.00
PKI's Earnings Yield (Greenblatt) (%) is ranked higher than
69% of the 189 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.10 vs. PKI: 4.00 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
PKI' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 1.7  Med: 4.30 Max: 9.4
Current: 4
1.7
9.4
Forward Rate of Return (Yacktman) (%) 20.27
PKI's Forward Rate of Return (Yacktman) (%) is ranked higher than
79% of the 57 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 11.03 vs. PKI: 20.27 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
PKI' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -2.5  Med: 10.75 Max: 43.7
Current: 20.27
-2.5
43.7

More Statistics

Revenue(Mil) $2262
EPS $ 1.88
Beta0.64
Short Percentage of Float2.85%
52-Week Range $39.50 - 54.52
Shares Outstanding(Mil)111.93

Analyst Estimate

Dec16 Dec17 Dec18
Revenue(Mil) 2,336 2,416 2,542
EPS($) 2.74 3.03 3.33
EPS without NRI($) 2.74 3.03 3.33

Latest Earnings Webcast

Call starts at Feb 04, 2016 05:00 PM EST

» More Conference Calls

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:WST, BAX, COV, TMO, COO » details
Traded in other countries:PKN.Germany,
PerkinElmer Inc is a Massachusetts corporation, founded in 1947. The Company provides products, services and solutions to the diagnostics, research, environmental, industrial and laboratory services markets. Through its advanced technologies, solutions, and services, it addresses critical issues that help to improve the health and safety of people and their environment. The Company reports its business in two segments: Human Health and Environmental Health. Its Human Health segment concentrates on developing diagnostics, tools and applications to help detect diseases earlier and more accurately and to accelerate the discovery and development of critical new therapies. Within the Human Health segment, it serves both the Diagnostics and Research Markets. In Diagnostics Markets it provides early detection for genetic disorders from pre-conception to early childhood, as well as digital x-ray flat panel detectors and infectious disease testing for the diagnostics market. In the Research market, it provides suite of solutions including reagents, liquid handling and detection and imaging technologies that enable researchers to improve the drug discovery process. Its main products for Human Health applications includes DELFIA Xpress screening platform, NeoGram MS/MS AAAC in vitro diagnostic kit, NeoBase Non-derivatized MS/MS kit, Specimen Gate informatics data management solution, XRD family of amorphous silicon digital x-ray flat panel detectors, Opera high content screening system and Operetta high content imaging system, UltraVIEW VoX 3D live cell imaging system and Asset Genius, an informatics-based business intelligence solution. Its Environmental Health segment provides products, services and solutions to facilitate the creation of safer food and consumer products, more secure surroundings and efficient energy resources. The Environmental Health segment serves the environmental, industrial and laboratory services markets. Its main products Environmental Health applications includes Clarus series of gas chromatographs, Flexar series of liquid chromatography and mass spectrometry instruments and LAMBDA UV/Vis series. The Company's main brands include AlphaLISA, AlphaScreen, Asset Genius, AutoDELFIA, BACS-on-Beads, BoBs, cell::explorer, Chem3D, ChemBioOffice, ChemDraw, Columbus, Datalytix, Dexela CMOS FPDs, Elsevier's Reaxys, EnLite, Ensemble for Biology, Ensemble for Chemistry and Ensemble for QA/QC. Its customers include pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors and government agencies. It competes with foreign and domestic organizations, which produce a comprehensive array of goods and services. The Company's operations are subject to various foreign, federal, state and local safety laws.
» More Articles for NYSE:PKI

Headlines

Articles On GuruFocus.com
Weekly CEO Sells Highlight: Family Dollar Stores Inc, Texas Instruments Inc, Mylan Inc, and PerkinEl Feb 08 2015 
Vanguard Health Care Fund Gains 27%, Buys 4 New Stocks Jul 31 2013 
The Best Dividends on April 18, 2012 Apr 18 2012 
PerkinElmer Inc. Reports Operating Results (10-K) Mar 01 2011 
PerkinElmer Inc. Reports Operating Results (10-Q) Nov 10 2010 
PerkinElmer Inc. Reports Operating Results (10-Q) Aug 10 2010 
PerkinElmer Inc. Reports Operating Results (10-Q) May 13 2010 
PerkinElmer Inc. (PKI) Chairman, President & CEO Robert F Friel sells 150,000 Shares Dec 17 2009 
PerkinElmer Inc. Reports Operating Results (10-Q) Aug 14 2009 
PerkinElmer Inc. Reports Operating Results (10-Q) May 15 2009 

More From Other Websites
PerkinElmer, Inc. (United States) Earnings Analysis: 2015 By the Numbers Feb 08 2016
PerkinElmer Q4 Earnings & Revenues Lag, FY16 Outlook Dull Feb 05 2016
Edited Transcript of PKI earnings conference call or presentation 4-Feb-16 10:00pm GMT Feb 05 2016
PERKINELMER INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Feb 04 2016
PerkinElmer misses Street 4Q forecasts Feb 04 2016
PerkinElmer misses Street 4Q forecasts Feb 04 2016
PerkinElmer 2016 forecast short of Wall Street estimates Feb 04 2016
PerkinElmer Announces Financial Results for Fourth Quarter and Full Year 2015 Feb 04 2016
Q4 2015 PerkinElmer Inc Earnings Release - After Market Close Feb 04 2016
PerkinElmer (PKI) Set to Beat Q4 Earnings Estimate Feb 01 2016
PerkinElmer Board Declares Quarterly Dividend Jan 28 2016
PerkinElmer to Hold Earnings Call on Thursday, February 4, 2016 Jan 08 2016
PerkinElmer, Inc. (United States) breached its 50 day moving average in a Bearish Manner : January... Jan 08 2016
Coverage initiated on PerkinElmer by Deutsche Bank Jan 07 2016
These Massachusetts public companies have significant business exposure in China Jan 07 2016
Clean Harbors Promotes Michael Battles to Chief Financial Officer Jan 06 2016
PerkinElmer, Inc. (United States) breached its 50 day moving average in a Bearish Manner : December... Dec 21 2015
XLV Has Impressed Investors in December Dec 17 2015
PerkinElmer to Present at J.P. Morgan 34th Annual Healthcare Conference Dec 15 2015
PerkinElmer, Inc. (United States) breached its 50 day moving average in a Bearish Manner : December... Dec 10 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK